ASCP Supports Consistent Terms in Testing in Precision Medicine

ASCP is pleased to announce its support for A White Paper on the Need for Consistent Terms for Testing in Precision Medicine. The paper represents the collective effort of a working group comprised of patient advocacy organizations, professional societies, and industry partners dedicated to identifying and adopting consistent biomarker and germline genetic testing terminology for patient communication. At least 33 terms related to biomarker, genetic and genomic testing in cancer are used in patient education today. This disparate terminology is one patient-identified reason for confusion: impeding effective communication and understanding about what testing means for their care. A unified voice will help the medical community and patients achieve common understanding about the benefits of testing. ASCP invites you to join with us and the other Working Group members in our commitment to adopt agreed upon terminology. #CancerTestingTerms #PrecisionMedicine #Cancer  http://ow.ly/3PGX50AiKvi 

To read more articles from this issue of ePolicy, click here. To learn more about ePolicy News and access past newsletters and articles, click here.

For more information regarding ASCP's advocacy initiatives and policy positions, please contact ASCP's Center for Public Policy at (202) 408-1110.  

ASCP ePolicy News is supported by an unrestricted grant from Hologic.